You are here

High-affinity monoclonal antibodies that target Burkholderia Polysaccharide

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-C-0005
Agency Tracking Number: C2-0485
Amount: $469,729.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD14-105
Solicitation Number: 14.1
Timeline
Solicitation Year: 2014
Award Year: 2018
Award Start Date (Proposal Award Date): 2017-12-20
Award End Date (Contract End Date): 2020-02-13
Small Business Information
1664 N. Virginia St. Applied Research Facility MS 328
Reno, NV 89557
United States
DUNS: 078634704
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Vydehi Kanneganti
 Principal Scientist
 (775) 354-6465
 vkanneganti@dxdiscovery.com
Business Contact
 David Maine
Phone: (775) 376-1191
Email: dmaine@dxdiscovery.com
Research Institution
N/A
Abstract

The purpose of this contract is to develop high affinity antibodies that are specific to Burkholderia surface expressed polysaccharides. These monoclonal antibodies (mAbs) can then be used to develop diagnostics and therapeutics for melioidosis and glanders; two infectious diseases caused by the Tier 1 biothreats Burkholderia pseudomallei and mallei, respectively. The SBIR funded work to date developed and characterized new and existing antibodies that we anticipate will lead to substantial advancements in the diagnosis and treatment of melioidosis and glanders. A number of lead mAbs studied during Phase I and II have been integrated into a lateral flow immunochromatographic assay (LFI) for the rapid detection of B. pseudomallei and mallei capsular polysaccharide (CPS). This project is a collaborative effort with InBios International (Seattle WA); a manufacturer of FDA approved rapid diagnostic tests for infectious diseases. CPS is a very encouraging target that can be used to diagnose acute melioidosis and glanders infections. However, the current LFI that was recently developed appears to lack the sensitivity needed to detect CPS in a significant number of patient samples. The goal of this enhancement period is to develop sensitive assays to determine the concentration of CPS within melioidosis patient samples (serum and urine).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government